There is need for a prospective longitudinal study of hyperuricaemia in chronic heart failure in order to evaluate its usefulness in assessing severity of the disease.
REFERENCES
1. Murphy JG, Lloyd MA, editors. Mayo Clinic Cardiology: Coincise Textbook. 3rd ed.
Rochester, MN: Mayo Clinic Scientific Press;2007.p. 1101
2. Libby P, Bonow RO, Mann DL, Zipes DP, editors. Braunwald’s Heart Disease: A
Textbook of Cardiovascular Medicine. 8th ed. Philadelphia (PA): Saunders Elservier; 2007. p.
611-39
3. Cabral TTJ, Claude AJ, Samuel K, Alessando G, Sylvia C, Alessando F, et al. Occurrence, aetiology and challenges in the management of congestive heart failure in sub-saharan Africa: experience of the Cardiac Centre in Shisong, Cameroon. The Pan
African Medical Journal.2011;8:11
4. Kannel WB. Incidence and epidemiology of heart failure. Heart Fail Rev 2000;5:167.
5. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M et al. Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005):
The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115.
6. Connell JB, Bristow M. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1993;13: S107–12.
7. Haldeman GA, Croft JB, Giles WH, Rashidee A. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J 1999;137:352–60.
8. Bardgett HP, Dixon M, Beeching NJ. Increase in hospital mortality from noncommunicable disease and HIV-related conditions in Bulawayo, Zimbabwe, between 1992 and 2000. Trop Doct 2006;36(3):129-31.
9. Kingue S, Dzudie A, Menanga A,Akono M, Ouankou M, Muna W. A new look at adult chronic heart failure in Africa in the age of the Doppler echocardiography: experience of the medicine department at Yaounde General Hospital. Ann Cardiol Angeiol (Paris)
2005;54(5):276-83
10. Mayosi BM. Contemporary trends in the epidemiology and management of cardiomyopathy and pericarditis in sub-Saharan Africa. Heart 2007; 93(10):1176-83.
11. Murdoch DR, Love MP, Robb SD, McDonagh TA, Davie AP, Ford I et al. Importance of heart failure as a cause of death. Changing contribution to overall mortality and coronary heart disease mortality in Scotland 1979–1992. Eur Heart J 1998; 19:1829–35.
12. Sliwa K, Damasceno A, Mayosi BM. Epidemiology and aetiology of cardiomyopathy in Africa. Circulation 2005; 112: 3577–83.
13. Agomouh DI, Unachukwu CN. Pattern of non-communicable diseases among medical admissions in Port Harcourt, Nigeria. Niger Med Pract. 2007;51:45–50
14. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR et al.
Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med 1999; 159:29–34.
15. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C et al. Uric acid and survival in chronic heart failure. Validation and application in metabolic, functional and hemodynamic staging. Circulation 2003; 107:1991–97.
16. Leyva F, Anker SD, Godsland IF, Teixeira M, Hellewell PG, Kox WJ, et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 1998; 19:1814–22.
17. Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors.
Harrison’s Principles of Internal Medicine. 18th ed. New York: Mc Graw Hill, Medical; 2012.
p. 1443-53, 2444-47.
18. Grum CM, Ketai LH, Myers CL, Shlafer M. Purine efflux after cardiac ischemia:
relevance to allopurinol cardioprotection. Am J Physiol 1987; 252:H368-73.
19. Hare JM, Johnson RJ. Uric Acid Predicts Clinical Outcomes in Heart Failure. Insights Regarding the Role of Xanthine Oxidase and Uric Acid in Disease Pathophysiology.
Circulation. 2003; 107:1951-53.
20. Bergamini C, Cicoira M, Rossi A, Vassanelli C. Oxidative stress and hyperuricaemia:
Pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure.Eur J Heart Fail 2009; 11:444 – 52.
21. Kittleson MM, Hare JM. Xanthine oxidase inhibitor: an emerging class of drugs for heart failure. Eur Heart J; 2005(26):1458-60.
22. Ekundayo OJ, Dell’Italia LJ, Sanders PW, Arnett D, Aban I, Love T.E, et al. Association between hyperuricemia and incident heart failure among older adults: A propensitymatched study. Int J Cardiol 2010; 142(3):279-87.
23. Krishnan E. Gout and the risk for incident heart failure and systolic dysfunction. BMJ Open 2012; 2:e000282.
24. The Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the Diagnosis and Treatment of Chronic Heart Failure. Eur Heart J 2001; 22:1527 – 60.
25. Thomas S, Rich MW. Epidemiology, pathophysiology, and prognosis of heart failure in the elderly. Heart Fail Clin 2007; 3:381-7.
26. Aronow WS. Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure. Cardiol Rev 2006; 14:108-24.
27. Thomas S, Rich MW. Epidemiology, pathophysiology, and prognosis of heart failure in the elderly. Clin Geriatr Med 2007; 23:1-10.
28. Leyva F, Anker S, Swan J W, Godsland IF, Wingrove CS,Chua TP et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997;
18:858-65.
29. Doehner W, Haehling SV, Anker SD. Uric acid as a Prognostic Marker in Acute Heart Failure — New expectations from an old molecule. Eur J Heart Fail 2007; 9(5):437 – 39.
30. Cortina A, Reguero J, Segovia E, Rodríguez Lambert JL, Cortina R, Arias JC et al.
Prevalence of heart failure in Asturias (a region in the north of Spain). Am J Cardiol 2001; 87:
1417–9.
31. Mosterd A, Hoes AW, de Bruyne MC, Deckers JW, Linker DT, Hofman A et al.
Prevalence of heart failure and left ventricular dysfunction in the general population: the Rotterdam Study. Eur Heart J 1999; 20:447–55.
32. Nielsen OW, Hilden J, Larsen CT, Hansen JF. Cross-sectional study estimating prevalence of heart failure and left ventricular systolic dysfunction in community patients at risk. Heart 2001; 86:172–8.
33. Ceia F, Fonseca C, Mota T,Ceia F, Fonseca C, Mota T, et al. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail 2002; 4:531–9.
34. Devereux RB, Roman MJ, Liu JE, Welty TK, Lee ET, Rodeheffer R et al. Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the Strong Heart Study. Am J Cardiol 2000; 86:1090–6.
35. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971; 285(26):1441-6.
36. Mendez GF, Cowie MR. The Epidemiological Features of Heart Failure in Developing Countries: A Review of the Literature. International Journal of Cardiology. 2001;
80(23):213–19.
37. Cowie MR, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Swesh V et al.
Incidence and aetiology of heart failure; a population- based study. Eur Heart J. 1999; 20(6):
421-8
38. Kannel WB. Epidemiological aspect of heart failure. Cardiol Clin. 1989; 7(1): 1-9
39. Remes J, Reunanen A, Aromaa A, Pyorala K. Incidence of heart failure in eastern Finland:
a population- based surveillance study. Eur Heart J. 1992; 13(5)588-93
40. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK. Long term trends in the incidence of and survival with heart failure. Eur Heart J. 2002;347: 1397
41. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole – Wilson PA, Sutton GC, et al. The Epidemiology of Heart Failure. Eur Heart J 1997;18:208 – 25.
42. Ho KK, Pinsky JL, Kannel WB, Levy D. The Epidemiology of Heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22:64.
43. Khatibzadeh S, Farzadfar F, Oliver J, Ezzati M, Moran A. Worldwide risk factors for heart failure: A systematic review and pooled analysis. Int J Cardiol 168: 1186-94.
44. Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D,Mensah GA, et al.
Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2008; 117: 2544-65.
45. Oyati AI, Danbauchi SS, Alhassan MA, Isah MS. Diastolic dysfunction in persons with hypertensive heart failure. J Natl Med Assoc 2004; 96(7): 968–73.
46. Ojji DB, Alfa J, Ajayi AO, Mamven MH, Falase AO. Pattern of heart failure in Abuja, Nigeria: an echocardiographic study. Cardiovasc J Afr 2009; 20: 349-52.
47. Onwuchekwa AC, Asekomeh GE. Pattern of heart failure in a Nigerian teaching hospital.
Vasc Health Risk Manag 2009; 5:745-50.
48. Amoah AG, Kallen C. Aetiology of heart failure as seen from a National Cardiac Referral Centre in Africa. Cardiology 2000; 93(1-2):11-8.
49. Jamison DT, Feachem RG, Makgoba MW, Bos ER, Baingana FK, Hofman KJ, et al, editors. Disease and Mortality in Sub-Saharan Africa. 2nd ed. Washinton DC: World Bank;
2006. p. 305-28
50. Owusu IK, Boakye YA. Prevalence and Aetiology of Heart Failure in Patients Seen at a Teaching Hospital in Ghana. J Cardiovasc Dis Diagn.2003;1: 131.
51. Karaye KM, Sani MU. Factors associated with poor prognosis among patients admitted with heart failure in a Nigerian tertiary medical centre: a cross-sectional study. BMC Cardiovascular Disorders 2008; 8:16
52. Griffin BP, Callahan TD, Menon V, Wu WM, Cauthen CA, Dunn JM, editors. Manual of cardiovascular medicine 4th ed. Philadelphia PA: Lippincott Williams & Wilkins; 2013. p.
126-49
53. Delgado lll RM, Willerson JT. Pathophysiology of Heart Failure: A Look at the Future.
Texas Heart Institute journal. 1999; 26(1): 28-33.
54. Haywood GA, Tsao PS, von der Leyen HE, Mann MJ, Keeling PJ, Trindade PT, et al.
Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996;
93:1087-94.
55. Oral H, Kapadia S, Nakano M, Torre-Amione G, Lee J, Lee- Jackson D, et al. Tumor necrosis factor-alpha and the failing human heart. Clin Cardiol 1995; 18(9 Suppl 4):20-7.
56. Habib FM, Springall DR, Davies GJ, Oakley CM, Yacoub MH, Polak JM. Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet
1996; 347:1151-5.
57. Benedict CR. Neurohumoral aspects of heart failure. Cardiol Clin 1994; 12:9-23.
58. Hosenpud JD, Greenberg BH, editors. Congestive heart failure: pathophysiology, diagnosis, and comprehensive approach to management. New York: Springer-Verlag, 1994: 13-4.
59. Aronow WS. Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure. Cardiology in Review. 2006;14(3): 108-24.
60. Katz AM. The cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart. Ann Intern Med 1994; 121:363-71.
61. Ferguson DW, Berg WJ, Sanders JS, Roach PJ, Kempf JS, Kienzle MG.
Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation 1989; 80:65-77.
62. Benedict CR. Neurohumoral aspects of heart failure. Cardiol Clin 1994; 12:9-23.
63. Wei CM, Lerman A, Rodeheffer RJ, McGregor CG, Brandt RR, Wright S, et al.
Endothelin in human congestive heart failure. Circulation 1994; 89:1580-6.
64. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS et al.
ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995
Guidelines for the Evaluation and Management of Heart Failure). Circulation. 2001; 104:2996 –3007.
65. Chatterjee K, Massie B. Systolic and diastolic heart failure: differences and similarities.
Journal of Cardiac Failure 2007; 13(7):569-76
66. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation. 2000; 101:2118–21.
67. Sohn DW, Chai IH, Lee DJ, Kim HC, Kim HS, Oh BH et al. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol 1997;30:474-80
68. Kitabatake A, Inoue M, Asao M, Tanouchi J, Masuyama T, Abe H et al. Transmitral blood flow reflecting diastolic behavior of the left ventricle in health and disease: a study by pulsed Doppler technique. Jpn Circ J 1982;40:92-102.
69. Oyati AI and Danbauchi SS. Diastolic heart failure: are there specific bedside clinical markers for its diagnosis? Annals of African Medicine Vol. 4, No. 3; 2005;4(3): 96 – 8 70. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic
function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004;
43:317e27.
71. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al.
Recommendations for chamber quantification. Eur J Echocardiography 2006;7: 79e108.
72. Varela-Roman A, Grigorian L, Barge E, Bassante P, de la Pen˜a MG, Gonzalez-Juanatey JR. Heart failure in patients with preserved and deteriorated left ventricular ejection fraction. Heart 2005; 91:489–94.
73. Jeptha PC, Seth IS, Yongfei W, Saif SR, Dennis TK, Farid J, et al. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatient with heart failure. J Am Coll Cardiol 2003; 42(4):736-42.
74. Hurst JW, Morris DC, Alexander RW. The use of the New York Heart Association's classification of cardiovascular disease as part of the patient's complete Problem List. Clin Cardiol 1999; 22(6):385-90.
75. McAlister FA, Teo KK, Taher M, Montague TJ, Humen D, Cheung L et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure.
Am Heart J 1999; 138: 87–94.
76. Muntwyler J, Abetel G, Gruner C, Follath F. One-year mortality among unselected outpatients with heart failure. Eur Heart J 2002;23:1861–6.
77. Guazzi M, Dickstein K, Vicenzi M, Arena R. Six Minute Walk Test and
Cardiopulmonary Exercise Testing in Patients with chronic heart failure circulation 2009:
2; 549 –55.
78. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW et al. The 6minute walk a new measure of exercise capacity in patients with chronic heart failure.
Can. Med. Assoc. J. 1985, 132: 919-923.
79. Anker SD, Leyva SD, Poole-Wilson PA, Coats AJS. Uric acid as an independent predictor of impaired prognosis in patients with chronic heart failure. J Am Coll Cardiol 1998;
31:154A.
80. Ketai L, Simon R, Kreit J. Plasma hypoxanthine and exercise. Am Rev Respir Dis 1987;
136:98-101.
81. Nees S, Bock M, Herzog V, Becker B, DesRosiers C, Gerlach E. The adenine nucleotide metabolism of the coronary endothelium: Implications for the regulation of coronary flow by adenosine. In: Stefanovich V, Rudolphi K, Schubert P, eds. Adenosine. Receptors and modulation of cell function. Oxford: IRL Press Limited, 1984: 419-36.
82. Nees S, Gerbes A, Gerlach E. Isolation, identification, and continuous culture of coronary endothelial cells from guineapig hearts. Eur J Cell Biol 1981; 24: 287-97
83. Daniel IF, Duk-Hee K. Richard J. J. Uric acid and cardiovascular risk. N Engl J Med 2008;
359:1811-21.
84. Ekelund UE, Harrison RW, Shokek O, Thakkar RN, Tunin R.S, Senzaki H, et al.
Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res 1999; 85:437–
45.
85. Saugstad OD. Role of xanthine oxidase and its inhibitor in hypoxia: reoxygenation injury.
Pediatrics 1996; 98:103–7.
86. Roch-Ramel F, Guisan B, Diezi J. Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles. J Pharmacol Exp Ther 1997; 280:839–
45.
87. Filippatos GS, Ahmed MI, Gladden JD, Mujib M, Aban IB, Love TE, et al.
Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Eur Heart J 2011; 32:712–20.
88. Doehner W, von Haehling S, Anker SD. Uric acid in CHF: marker or player in a metabolic disease? Int J Cardiol 2007; 115:156-8.
89. Parish RC, Evans JD. Inflammation in chronic heart failure. Ann Pharmacother 2008;
42:1002–16.
90. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumour necrosis factor in severe chronic heart failure. N Engl J Med 1990;323: 236–74
91. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, et al. Tumour necrosis factor soluble receptors in patients with various degrees of congestive heart failure.
Circulation 1995; 92:1479–86.
92. Anker SD, Egerer KR., Volk HD, Kox WJ, Poole-Wilson PA, Coats AJ. Elevated soluble
CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 1997;
79:1426–30
93. Tsutamoto T, Hisanaga T, Fukai D, Wada A, Maeda Y, Maeda K, et al. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-concentration in patients with chronic congestive heart failure. Am J Cardiol 1995; 76:803–8.
94. Freeman BA, Crapo JD. Biology of disease: free radicals and tissue injury. Lab Invest 1982;
47:412–26.
95. Hess ML, Okabe E, Kontos HA. Proton and free oxygen radical interaction with the calcium transport system of cardiac sarcoplasmatic reticulum. J Mol Cell Cardiol 1981; 13:767–72.
96. Cicoira M, Zanolla L, Rossy A, Golia G, Franceschini L, Brighetti G, et al. Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy. Am Heart J 2002; 143:1107-11.
97. Carlsen JE, Kober L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990;300:
975–8.
98. Krishnan E. Hyperuricemia and Incident Heart Failure. Circ Heart Fail 2009; 2:556-862.
99. Reyes AJ. The increase in serum uric acid concentration caused by diuretics might be beneficial in heart failure. Eur J Heart Fail 2005; 7:46 –7.
100. Regoli F., Winston G. W. Quantification of total oxidant scavenging capacity of antioxidants for peroxynitrite, peroxyl radicals, and hydroxyl radicals. Toxicol Appl Pharmacol 1999; 156:96–105.
101. Teng RJ, Ye YZ, Parks DA, Beckman JS. Urate produced during hypoxia protects heart proteins from peroxynitrite-mediated protein nitration. Free Radic Biol Med 2002;
33:1243–9.
102. Trostchansky A, Ferrer-Sueta G, Batthyany C, Botti H, Batinic-Haberle I, Radi R et al.
Peroxynitrite flux-mediated LDL oxidation is inhibited by manganese porphyrins in the presence of uric acid. Free Radic Biol Med 2003; 35:1293– 300.
103. Muraoka S, Miura T. Inhibition by uric acid of free radicals that damage biological molecules. Pharmacol Toxicol 2003; 93:284– 9.
104. Swan JW, Walton C, Godsland IF, Clark AL, Coats AJS, Oliver MF. Insulin resistance in heart failure. Eur Heart J 1994; 15: 1528-32.
105. Liedtke A, Hugues H, Neely J. Effects of excess glucose and insulin on glycolytic metabolism during experimental myocardial ischemia. Am J Cardiol 1976; 38: 17-27.
106. Zaria. https://en.wikipedia.org/wiki/Zaria . Accessed on 28/2/2013.
107. Araoye MO. Research methodology with statistics for health and social sciences. Ilorin, Nigeria: Nathadex publishers; 2003. p.116-7,117.
108. Swash M, Glynn M. Hutchison’s clinical methods: an integrated approach to clinical practice. 22nd ed. Edinburgh: Saunders Elservier;2007. p. 75-97
109. World Health Organisation (2006) “BMI Classifications”
http://www.who.int/bmi/index.jsp?introPage=intro_3.html
110. Electrocardiogram procedure.
http://shs-manual.ucsc.edu/policy/electrocardiogramprocedure. Accessed 22/6/16
111. Roberto ML, Michelle B, Richard BD, Frank AF, Elyse F, Patricia AP et al.
Recommendations for chamber quantification. Eur J Echocardiography 2006; 7:79-108.
112. Arturo E, Frank F, Patrizio L, Luigi B, Rio A, Mark M et al. European Association of Echocardiography Recommendations for standardization of performance, digital storage and reporting of echocardiographic studies. European Journal of Echocardiography 2008;
9:438–48.
113. Shivaraja Shankara YM. Laboratory manual for practical biochemistry. New Delhi:
Jaypee Brothers Medical publishers; 2008. p. 83-4.
114. Bittner V., Weiner D.H., Yusuf S, Rogers WJ, Mclntyre KM, Bangdiwala SI et al.
Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA 1993; 270:1702-7.
115. Richards A.M., Troughton R., Lainchbury J., Doughty R., Wright S. Guiding and monitoring of heart failure therapy with NT-ProBNP: concepts and clinical studies. J Card Fail 2005; 11(5 Suppl):S34-7.
116. Shah M.R., Claise K.A., Bowers M.T. Bhapkar M, Little J, Nohria A et al. Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial. Am Heart J 2005;
150:893-8.
117. Working Group on Cardiac Rehabilitation and Exercise Physiology, Working Group on Heart Failure of the European Society of Cardiology .Recommendations for exercise testing in chronic heart failure patients. Eur Heart J 2001; 22:37-45.
118. Ajuluchukwu J, Mbakwem A, Ekure E, Okoromah C, Oladipo O. Reliability and Accuracy of Pointof- Care Amino-Terminal ProBrain Natriuretic Peptide in Congestive Heart Failure Patients. The Internet Journal of Cardiology. 2010;9(2):1-15.
119. Ekure EN, Okoromah CA, Ajuluchukwu JN, Mbakwem A, Oladipo J. Diagnostic
Usefulness of N-terminal Pro-brain Natriuretic Peptide among Children with Heart Failure in a Tertiary Hospital in Lagos, Nigeria. West African Journal of Medicine. 2011;
30(1):29-34.
120. Gagliardi AC, Miname MH, Santos RD. Uric acid: A marker of increased
cardiovascular risk. Atherosclerosis 2008. doi:10.1016/ j.atherosclerosis.2008. 05.022.
121. Saavedra W F, Paolocci N, St. John ME, Skaf MW, Stewart GC, Xie JSet al. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res 2002; 90: 297-304.
122. Pearson GD, Veille JC, Rahimtoola S, Hsia J, Oakley CM, Hosenpud JD, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. Jama. 2000 Mar 1;
283(9):1183-8.
123. Ford L, Abdullahi A, Anjorin FI, Danbauchi SS, Isa MS, Maude GH et al. The outcome of peripartum cardiac failure in Zaria, Nigeria. QJM. 1998;91(2):93–103.
124. Wenger NK. The greying of cardiology: implications for management. Heart 2007; 167:
490–6.
125. Goldberg RJ, Ciampa J, Lessard D, Meyer TE, Spencer FA. Long-term survival after heart failure: a contemporary population-based perspective. Arch intern Med 2007; 167: 490–6.
126. Hoeper MM, Hohlfeld JM, Fabel H. Hyperuricaemia in patients with right or left heart failure. Eur Respir J. 1999; 13:682–5.
127. Leyva F, Chua TP, Anker SD, Coats AJ. Uric acid in chronic heart failure: a measure of the anaerobic threshold. Metabolism 1998; 47:1156– 9.
128. Hamaguchi S, Furumoto T, Tsuchihashi-Makaya M, Goto K, Goto D, Yokota T et al.
Hyperuricemia predicts adverse outcomes in patients with heart failure. Int J of Cardiol,
2011;151(2):143–7.
129. Jankowska EA, Ponikowska B, Majda J, Zymlinski R, Trzaska M, Reczuch K et al, Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure. Int J Cardiol. 2007;115:151–5.
130. Tereshchenko SN, Levchuk NN, Drozdov VN, Moiseev VS. Level of blood uric acid in patients with post infarction heart failure. Ter Arkh 2000; 72:57 –60.
131. Lainscak M, von Haehling S, Anker SD. Natriuretic peptides and other biomarkers in chronic heart failure: From BNP, NT-proBNP, and MR-proANP to routine biochemical markers. International Journal of Cardiology. 2009; 3:303–11.
132. Vakilian F, Rafighdoost AA, Rafighdoost AH, Amin A, Salehi M. Liver Enzymes and Uric acid in Acute Heart Failure. Res Cardiovasc Med. 2015;4(4):e22988.
133. Murai K, Asai K, Oka E, Kubota Y, Nakamura S, Inui K et al. Importance of Peak
Uric Acid in Patients with Acute Heart Failure Syndromes. j.cardfail.2014;20(10):S181 134. Park H,Kim H, Sohn J, Shin H, Cho Y, Yoon H et al. Combination of Uric Acid and
NT-ProBNP: A More Useful Prognostic Marker for Short-Term Clinical Outcomes in Patients with Acute Heart Failure. Korean J Intern Med. 2010;25(3): 253–59.
135. Doehner W, Rauchhaus M, Florea VG, Sharma R, Bolger AP, Davos CH et al. Uric acid in cachectic and non-cachectic patients with chronic heart failure: relationship to leg vascular resistance. Am Heart J. 2001; 141:792–9.